Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer

Rhea-AI Summary

Evotec (NASDAQ:EVO) named Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer on April 1, 2026.

Dr. Khan brings over 15 years of international leadership and a track record of closing $7 billion+ in deals; he previously served at Iktos, Proteros and Schrödinger. Evotec has >4,800 employees and >100 proprietary R&D assets.

Positive

• Appointment of Dr. Ashiq H. Khan as Chief Commercial Officer
• Dr. Khan has 15+ years international biotech, CRO and AI experience
• Track record of closing $7 billion+ in collaboration and deals
• Evotec operates a global team of 4,800+ experts

Negative

• None.

News Market Reaction – EVO

+1.60%

+1.60% Session close to close

In the Apr 1 session, EVO gained 1.60%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Evotec’s focus on strengthening its commercial engine by appointing a C...

Analysis

This announcement highlights Evotec’s focus on strengthening its commercial engine by appointing a Chief Commercial Officer with experience closing over $7 billion in deals. It follows recent strategic milestones in partnerships, grants, and portfolio optimization. Investors may watch how this leadership change supports monetization of Evotec’s more than 100 proprietary R&D assets, relationships with all Top 20 pharma companies, and integration of AI-driven platforms into commercial offerings.

Key Figures

Leadership experience: over 15 years Deal value closed: more than $7 billion Top Pharma partners: Top 20 Pharma +5 more

8 metrics

Leadership experience over 15 years Dr. Khan’s international leadership experience in biotech and CROs

Deal value closed more than $7 billion High-value standalone, integrated, and collaboration agreements

Top Pharma partners Top 20 Pharma Evotec works with all Top 20 Pharma companies

Biotech partners over 800 biotechs Number of biotech partners Evotec collaborates with

Proprietary assets over 100 R&D assets Size of Evotec’s proprietary R&D portfolio

Global workforce more than 4,800 experts Evotec’s global team size across Europe and the U.S.

Current share price $2.50 Pre-news price, <b>47.92%</b> below 52-week high of <b>4.8</b>

1-day move 5.93% Price change over the last 24 hours before this news

Historical Context

5 past events · Latest: 2026-03-23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
2026-03-23	Government contract	Positive	-2.1%	BARDA-backed project for Ebola and Sudan virus antibody manufacturing optimization.
2026-03-19	Clinical milestone	Positive	+0.4%	Bristol Myers Squibb begins Phase 1 study, triggering $10 million payment.
2026-01-08	AI platform grant	Positive	+1.4%	Gates Foundation grant funds ten AI-driven J.MD™ projects over three years.
2026-01-02	Executive appointment	Positive	+3.3%	Appointment of Dr. Sarah Fakih to lead integrated communications and IR.
2025-12-08	Asset sale deal	Positive	-3.5%	Toulouse site sale to Sandoz with potential payments over US$650m plus royalties.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has generally been positive, with mixed immediate price reactions: three upticks and two pullbacks, suggesting that good news has not always translated into near-term gains.

Recent Company History

Over the past months, Evotec reported strategic wins including BARDA selection for Ebola/Sudan virus antibody manufacturing (up to $10 million), a $10 million milestone from Bristol Myers Squibb for a Phase 1 study, and a Gates Foundation-backed AI initiative funding ten J.MD™ projects over three years. Corporate actions included appointing Dr. Sarah Fakih to lead Global Communications and IR and closing the Toulouse site sale to Sandoz with potential payments above US$650m. Today’s Chief Commercial Officer hire continues this pattern of strengthening partnerships and leadership.

Key Terms

cro, ai-driven, drug discovery, cell therapies, +3 more

7 terms

cro technical

"leadership experience in biotech, CRO and AI-driven platform businesses"

CRO stands for Contract Research Organization, a company that helps pharmaceutical and biotech firms manage and carry out clinical trials to test new medicines. For investors, CROs are important because they enable drug companies to develop new treatments more efficiently, potentially accelerating the path to market and affecting the company's growth prospects and success.

ai-driven technical

"leadership experience in biotech, CRO and AI-driven platform businesses"

AI-driven describes products, services, processes or decisions that rely on artificial intelligence—software that detects patterns in data and makes predictions or choices without step-by-step human direction. For investors it signals potential for faster growth, lower operating costs or new revenue, but also new risks (model errors, data problems, regulatory limits); think of it like a smart thermostat that can save energy and money but can also misbehave if fed bad information.

drug discovery medical

"cutting-edge drug discovery platforms"

The process of finding and creating new medicines, starting with identifying a biological problem and then searching for molecules that can fix it; this involves lab research, computer modeling and early tests to narrow thousands of candidates down to a few promising leads. Investors care because successful drug discovery can create patents, long-term sales and big gains but is costly and risky—like designing a key for a specific lock: most attempts fail, but a working key can be very valuable.

cell therapies medical

"Our expertise spans small molecules, biologics, cell therapies and associated modalities"

Cell therapies are medical treatments that use living cells as the active medicine to repair, replace or reprogram damaged tissue or disease processes; the cells can come from the patient, a donor, or be made in a lab. For investors, they matter because they can offer long-lasting or curative effects unlike conventional drugs, but they also carry high research and manufacturing costs, complex regulation and scaling challenges—think of them as custom-built machines that can do remarkable work but are expensive and tricky to produce and deliver.

molecular patient databases medical

"supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling"

Molecular patient databases are organized collections of patients’ biological data—such as genetic sequences, protein levels, and other molecular tests—linked to clinical information like diagnoses and treatment outcomes. Like a searchable library that connects a book’s content to readers’ reactions, these databases help researchers and drug developers spot patterns, design targeted therapies, and predict who will benefit from a treatment, making them valuable for investors because they can accelerate drug development, create licensing opportunities, and influence regulatory and commercial success.

ipsc-based disease modeling medical

"platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling"

iPSC-based disease modeling uses patient-derived cells that have been reprogrammed back into a flexible, stem-like state and then grown into specific tissue types in the lab to recreate aspects of a disease. For investors this matters because these lab-grown, patient-specific models let researchers test drug effects and predict safety or efficacy earlier and more cheaply than human trials, acting like a focused rehearsal that can reduce development risk and speed decisions.

biologics medical

"Our expertise spans small molecules, biologics, cell therapies and associated modalities"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. Dr. Khan brings to Evotec over 15 years of international leadership experience in biotech, CRO and AI-driven platform businesses, with a distinguished track record of managing diverse transcontinental teams and closing more than $7 billion in high-value standalone, integrated, and collaboration agreements across the U.S., EU and APAC markets. In his role, Dr. Khan will spearhead the build-out of a globally integrated, fit-for-purpose commercial organization fully aligned with Evotec's scientific leadership and platform capabilities to deliver enhanced customer value and drive more robust, sustainable growth.

Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:

"Ashiq has demonstrated tremendous success driving growth in innovative areas like robotics, artificial intelligence and cutting-edge drug discovery platforms. His expertise is essential for executing the next stage of Evotec's transformation as a responsive drug discovery and development engine built around high-value services and capabilities. We are excited to have someone with his experience in recognizing and creating new opportunities at the helm of our commercial team."

Dr. Khan most recently served as Chief Business Officer at Iktos. Prior to that, he held leadership roles at Proteros and Schrödinger. He holds a Ph.D. in Neurobiology from the University of Cologne and business degrees from the Wharton Business School and INSEAD.

Dr. Ashiq H. Khan, Evotec's designated Chief Commercial Officer, added:

"Evotec is uniquely positioned to advance early-stage drug discovery and development, underpinned by its industry-validated platforms, deep scientific expertise, and proven commercial models. As new technologies continue to transform the field, I am fully committed to working with Evotec's exceptional scientific, operational, and business leaders to further strengthen our capabilities and drive the next generation of breakthrough therapies."

About Evotec SE

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us onLinkedIn and X/Twitter @Evotec.

Forward-looking statements

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor Relations and Media Contact

Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com

SOURCE: Evotec SE

View the original press release on ACCESS Newswire

FAQ

Who is Evotec (EVO) appointing as Chief Commercial Officer on April 1, 2026?

Evotec appointed Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. According to Evotec, he brings over 15 years of leadership across biotech, CRO and AI-driven platform businesses and prior roles at Iktos, Proteros and Schrödinger.

What commercial experience does Dr. Ashiq H. Khan bring to Evotec (EVO)?

Dr. Khan brings 15+ years of international leadership and deal experience. According to Evotec, he has closed more than $7 billion in standalone, integrated and collaboration agreements across the U.S., EU and APAC markets.

How will Dr. Khan's role affect Evotec's commercial organization and growth plans?

Dr. Khan will lead the build-out of a globally integrated commercial organization aligned with Evotec's platforms. According to Evotec, his remit is to deliver enhanced customer value and drive more robust, sustainable growth across services and integrated programs.

What are Dr. Khan's prior roles and education noted by Evotec (EVO)?

Dr. Khan most recently served as Chief Business Officer at Iktos and held roles at Proteros and Schrödinger. According to Evotec, he holds a Ph.D. in Neurobiology and business degrees from Wharton and INSEAD.

What scale and assets does Evotec cite alongside the CCO appointment (EVO)?

Evotec highlights a global team of 4,800+ experts and over 100 proprietary R&D assets. According to Evotec, its platforms include Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

Does Evotec (EVO) describe the geographic scope of Dr. Khan's deal experience?

Yes. Evotec notes Dr. Khan closed deals across the U.S., EU and APAC markets. According to Evotec, his agreements include standalone, integrated and collaboration arrangements covering multiple regions and modalities.